Tracy Hoang

Tracy Hoang is an Early-career researcher at The University of Western Australia's Medical School, affiliated with the Centre for Respiratory Health. She holds the position of Adjunct Research Fellow with active involvement in multiple cancer research projects focusing on tumor immunology and therapeutic development.

• University: The University of Western Australia
• School: Medical School
• Department: Centre for Respiratory Health
• Academic Rank: Research Fellow

Dr. Hoang completed her PhD research on glioblastoma, investigating cell cycle checkpoint inhibitors combined with standard therapy to induce tumor cell death through DNA damage accumulation. Her current work centers on mesothelioma and the interplay between the immune system and cancer, with expertise in flow cytometry analysis of immune cell populations and preclinical experiments including drug administration and imaging.

Her research spans tumor hypoxia imaging, PD-L1 dynamics in response to immunotherapy, and host genetic factors in asbestos-related diseases. Publications demonstrate strong focus on translational oncology with emphasis on imaging biomarkers, immunotherapy response mechanisms, and radiation therapy combinations. Key trends show progression from glioblastoma research to mesothelioma immunology with increasing emphasis on clinical translation and biomarker discovery.

Dr. Hoang serves as an investigator on four active research grants, including projects tracking PD-L1 modulation in mesothelioma using advanced imaging and developing zirconium-89 labelled antibodies for immunotherapy monitoring. Her collaborative network spans multiple institutions with significant contributions to understanding tumor-immune interactions in mesothelioma.

Her laboratory work involves preclinical imaging, flow cytometry, and cell line experimentation with particular expertise in irradiated mesothelioma models. Current projects utilize advanced in vivo imaging techniques to monitor therapeutic responses and develop novel imaging approaches for cancer treatment assessment.